Romidepsin (Romidepsin) Patent Expiration, LOE Window & CMS Spending
Romidepsin (Romidepsin) by Fresenius Kabi: Off-Patent Uncontested (0 AB Generics), 0 AB generics, $1.6M 2024 CMS Part D & Medicaid spend, and $8,700 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Fresenius Kabi |
| FDA Application & Pathway | N208574 (NDA) |
| Exclusivity / Cliff Horizon | Off-Patent Uncontested (0 AB Generics) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $1.6M |
| 2024 Medicare Part D Spend | $386K |
| 2024 Medicaid Spend | $1.2M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($8,700 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Fresenius / Fresenius Kabi across sibling Meru public-data platforms.